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Introduction
　Tumors of the nasal cavity and paranasal sinus are rare among head and neck neoplasms. 
However, the tumor types in this region vary widely and early detection is difcult because 
of the anatomical location.  There have been many cases in which the tumor has grown 
extensively before the appearance of any symptoms.
　For maxillary cancer, various reports have addressed the effects of radiation therapy, che-
motherapy with radiation therapy （including arterial injection）, en bloc resection by surgery, 
and fractional excision.  At present, there are wide interfacility variations in regard to the 
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treatment modalities for such patients.
　In this department, we provide treatment for head and neck malignancies with the inten-
tion of a permanent cure with preservation of organs and function.  We report the treat-
ment outcomes in five cases of maxillary cancer for which we utilized S-1 and nedaplatin 
with concurrent radiation therapy （SN therapy） from April 2005 to March 2009.
Patients and Methods
　We administered SN therapy to five patients with maxillary cancer in this department 
from April 2005 to March 2009.  With regard to histological type, all cases were identied 
as squamous cell carcinoma.
　The research parameters were age, sex, follow-up duration, TNM Classification （UICC 
Classication, 2002）, staging classication and treatment type.
　The SN regimen used involved two courses, each consisting of a 14-day oral administra-
tion of S-1 （80 mg / m2）, an intravenous infusion of Nedaplatin （90 mg / m2） on the fourth 
day and radiation therapy （1.2 Gy×2 / day） for three weeks.  The second course was initi-
ated after a one-week break 1, 2） （Fig. 1）.  Radiation therapy consisted of a total of 69.6 Gy. 
SN therapy is indicated for patients younger than 80 years old with a creatinine clearance 
of more than 60 ml / minute and the absence of serious liver or cardiac disease.  For 
patients over 75 years old the dosage is reduced to 70-80％ of the normal dosage.  Cispla-
tin, 5-FU and combination therapy with radiation are performed before SN therapy in our 
department.  For renal function disorders cisplatin is replaced by nedaplatin.
　The therapeutic protocol for maxillary cancer in this department is to administer radiation 
therapy after excision of the maxillary tumor in cases of T1 tumors.  For T2 and T3 cases, 
SN therapy is provided after excision of the maxillary tumor.  In T4 cases, one course of 
SN therapy is provided and excision of the maxillary tumor is performed two weeks later 
followed by the second course of SN therapy （Fig. 2）.  〔All the operations involved a 
Denker’s procedure.〕
Age / Sex
　The patient ages ranged from 29 to 67 years and the average age was 55.6 years.  The 
Fig. 1.  S-1, Nedaplatin / Concurrent chemoradiotherapy（SN Therapy）
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median age was 60 years of age.  All patients were male.
Follow-up Duration
　The follow-up duration ranged from 15 months to 45 months and the average follow-up 
period was 32.4 months.  The median value was 33 months.
TNM Classication / Staging Classication （UICC Classication, 2002）
　Four cases were classied as T4NOMO （Stage IV） and one case as T2NOMO （Stage II）.
Fig. 2.  Therapeutic strategy for maxillary cancer
Table 1.  Details of Treatment
Age / Sex classication
Progress after
SN therapy
Follow-up
（month） Outcome
1 62M T4
adjuvant chemotherapy
（S-1） 31m
surviving without
cancer
2 29M T4
Neck LN metastasis
Neck dissection
adjuvant chemotherapy
（UFT）
 45m
surviving without
cancer
3 58M T2 None 33m
surviving without
cancer
4 60M T4
Neck LN metastasis
Neck dissection
37m
surviving without
cancer
5 62M T4
Arterial injection
Cyber knife
Lung metastasis
15m
surviving with
cancer
All cases were NO MO.
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Results
Treatment Details （Table 1）
　The T2 case underwent an excision of the maxillary tumor followed by SN therapy.  The 
observation period was 33 months and the patient is presently living without cancer. （case 
3）
Fig. 3.  Sinus CT at rst examination
A tumor progressing to the oral cavity and the right nasal cavity 
from the left maxillary sinus.
Fig. 4.  Sinus CT after one course of SN therapy
The tumor is reduced.
Fig. 5.  Sinus CT after treatment
The tumor has disappeared.
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　Four cases were classified as T4.  These patients received one course of SN before 
undergoing an excision of the maxillary tumor.  The second course of SN therapy was then 
administered.  Three of these cases achieved a complete response （CR）.  In one case, the 
administration of S-1 as an adjunctive chemotherapy was performed for two weeks followed 
by a two-week break.  This pattern was performed for 12 months.  The observation period 
was 31 months and the patient is presently living without cancer.  （case 1, Fig. 3, 4, 5）
　In another case, UFT was administered as an adjunctive chemotherapy.  After ten months 
a cervical lymph node metastasis appeared.  This was surgically removed.  The observation 
period was 45 months and the patient is presently living without cancer. （case 2）
　Another of the T4 cases experienced a cervical lymph node metastasis after six months. 
This tumor was also removed surgically.  The observation period was 37 months and the 
patient is currently living without cancer. （case 4）
　The remaining case did not achieve a CR.  This patient received an arterial injection of 
docetaxel by the Seldinger method, followed by an arterial injection of 5FU from a super-
cial temporal artery.  A partial response （PR） was achieved.  The patient then underwent 
CyberKnife treatment （total 3500 cGy）, which resulted in local control, but lung metastasis 
subsequently occurred.  The follow-up duration was 15 months and the patient is currently 
living with cancer.  （case 5）
Discussion
　Tumors of the nasal cavity and paranasal sinus can be benign or malignant and can 
vary histologically.  According to our tumor statistics, 38.5％ of these tumors are benign 
and 61.5％ are malignant.  Papillomas comprise 25.0％ of cases, squamous cell carcinoma 
comprises 21.3％, malignant lymphoma comprises 19.3％, pseudotumors comprise 11.6％, 
malignant melanoma, malignant fibrous histiocytoma, rhabdomyosarcoma and plasmacytoma 
each comprise 3.8％, and hamartoma, hamangioma, small cell cancer and adenocarcinoma 
each comprise 1.9％.
　Since the report of combined therapy by Sato et al 3）, there has been significant prog-
ress with regard to the treatment of maxillary cancer, however inter-facility differences in 
therapeutic strategies exist.  There are several different methods for performing an en bloc 
resection and combined therapy.  At present, the use of medical treatments such as arterial 
injection chemotherapy, fractional excision and concurrent chemoradiotherapy vary depending 
on facility protocols.
　In this department, we have achieved favorable outcomes 1） using SN therapy for cancer 
of the head and neck2）.  In cases of maxillary cancer, we preserve the palate and eyeball 
with a combination of SN therapy and partial resection of the maxilla.  In four of the ve 
cases in this report, we were able to reduce the extent of surgery by administering SN 
therapy.  Function and morphology could therefore be preserved.  In the remaining case, 
however, an internal carotid invasion had already occurred at the time of diagnosis, and 
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radical resection was impossible.  Although we provided medical treatment according to 
departmental policy, the tumor persisted even after arterial injection chemotherapy.  This 
patient developed a lung metastasis which we controlled locally with CyberKnife treatment. 
This outcome demonstrates that CyberKnife treatment is a viable treatment option for cases 
of recurrence and PR.
　Previous studies have reported ve-year survival rates for maxillary cancer patients ranging 
from 45.0％-62.5％, regardless of treatment variability 6）.  For the preservation of the palate 
and eyeball however, outcomes vary between facilities and a rate of maxillary preserva-
tion of about 30.0％ has been reported 3）.  In this department, we administer SN therapy 
and perform partial resection of the maxilla.  The palate is preserved via resection of the 
sidewall of the nasal cavity only.  This treatment strategy maintains the QOL of patients 
by preserving function and morphology.  However, it is difcult to make comparisons with 
other reports with regard to the number of cases and follow-up duration.  We hope to 
increase the number of patients in future studies to add weight to these results.
Conclusions
　We reported the outcomes of SN therapy for ve cases of maxillary cancer.  SN therapy 
allowed a reduction in the extent of surgery in order to preserve function and morphology. 
To assess the effectiveness of this strategy, evaluation of the survival rates in addition to the 
effect preserving function and morphology is required.  Towards this goal, we will study an 
increased number of such cases in the future.
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